Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-524ff85a84e081511904d5b0500b5714",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-524ff85a84e081511904d5b0500b5714",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-524ff85a84e081511904d5b0500b5714",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-524ff85a84e081511904d5b0500b5714\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-524ff85a84e081511904d5b0500b5714</b></p><a name=\"composition-en-524ff85a84e081511904d5b0500b5714\"> </a><a name=\"hccomposition-en-524ff85a84e081511904d5b0500b5714\"> </a><a name=\"composition-en-524ff85a84e081511904d5b0500b5714-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/821/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - tolucombi</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/13/821/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp524ff85a84e081511904d5b0500b5714"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - tolucombi",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Tolucombi is and what it is used for</li><li>What you need to know before you take Tolucombi</li><li>How to take Tolucombi</li><li>Possible side effects</li><li>How to store Tolucombi</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What tolucombi is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What tolucombi is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"tolucombi-is-a-combination-of-two-active-substances-telmisartan-and-hydrochlorothiazide-in-one-tablet-both-of-these-substances-help-to-control-high-blood-pressure\">Tolucombi is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet. Both of these substances help to control high blood pressure.</h2><h2 id=\"telmisartan-belongs-to-a-group-of-medicines-called-angiotensin-ii-receptor-antagonists-angiotensin-ii-is-a-substance-produced-in-your-body-which-causes-your-blood-vessels-to-narrow-thus-increasing-your-blood-pressure-telmisartan-blocks-the-effect-of-angiotensin-ii-so-that-the-blood-vessels-relax-and-your-blood-pressure-is-lowered\">Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. Angiotensin II is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure. Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.</h2><p>Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure. High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range. Tolucombi (40 mg/12.5 mg, 80 mg/12.5 mg) is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan is used alone. Tolucombi (80 mg/25 mg) is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled by Tolucombi 80 mg/12.5 mg or in patients who have been previously stabilised by telmisartan and hydrochlorothiazide given separately.</p></div>"
}
},
{
"title" : "2. What you need to know before you take tolucombi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take tolucombi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"do-not-take-tolucombi\">Do not take Tolucombi</h2><h2 id=\"if-you-are-allergic-to-telmisartan-or-any-other-ingredients-of-this-medicine-listed-in-section-6\">if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6).</h2><h2 id=\"if-you-are-allergic-to-hydrochlorothiazide-or-to-any-other-sulfonamide-derived-medicines\">if you are allergic to hydrochlorothiazide or to any other sulfonamide-derived medicines.</h2><h2 id=\"if-you-are-more-than-3-months-pregnant-it-is-also-better-to-avoid-tolucombi-in-early-pregnancy-see-pregnancy-section\">if you are more than 3 months pregnant. (It is also better to avoid Tolucombi in early pregnancy-see pregnancy section.)</h2><h2 id=\"if-you-have-severe-liver-problems-such-as-cholestasis-or-biliary-obstruction-problems-with-drainage-of-the-bile-from-liver-and-the-gall-bladder-or-any-other-severe-liver-disease\">if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from liver and the gall bladder) or any other severe liver disease.</h2><h2 id=\"if-you-have-severe-kidney-disease\">if you have severe kidney disease.</h2><h2 id=\"if-your-doctor-determines-that-you-have-low-potassium-levels-or-high-calcium-levels-in-your-blood-that-do-not-get-better-with-treatment\">if your doctor determines that you have low potassium levels or high calcium levels in your blood that do not get better with treatment.</h2><h2 id=\"if-you-have-diabetes-or-impaired-kidney-function-and-you-are-treated-with-a-blood-pressure-lowering-medicine-containing-aliskiren-if-any-of-the-above-applies-to-you-tell-your-doctor-or-pharmacist-before-taking-tolucombi-warnings-and-precautions-talk-to-your-doctor-before-taking-tolucombi-if-you-are-suffering-or-have-ever-suffered-from-any-of-the-following-conditions-or-illnesses\">if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. If any of the above applies to you, tell your doctor or pharmacist before taking Tolucombi. Warnings and precautions Talk to your doctor before taking Tolucombi if you are suffering or have ever suffered from any of the following conditions or illnesses:</h2><h2 id=\"low-blood-pressure-hypotension-likely-to-occur-if-you-are-dehydrated-excessive-loss-of-body-water-or-have-salt-deficiency-due-to-diuretic-therapy-water-tablets-low-salt-diet-diarrhoea-vomiting-or-haemodialysis\">Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy (water tablets), low-salt diet, diarrhoea, vomiting, or haemodialysis.</h2><h2 id=\"kidney-disease-or-kidney-transplant\">Kidney disease or kidney transplant.</h2><h2 id=\"renal-artery-stenosis-narrowing-of-the-blood-vessels-to-one-or-both-kidneys\">Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).</h2><h2 id=\"liver-disease\">Liver disease.</h2><h2 id=\"heart-trouble\">Heart trouble.</h2><h2 id=\"diabetes\">Diabetes.</h2><h2 id=\"gout\">Gout.</h2><h2 id=\"raised-aldosterone-levels-water-and-salt-retention-in-the-body-along-with-imbalance-of-various-blood-minerals\">Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals).</h2><h2 id=\"systemic-lupus-erythematosus-also-called-lupus-or-sle--a-disease-where-the-body-s-immune-system-attacks-the-body\">Systemic lupus erythematosus (also called lupus or SLE ) a disease where the body s immune system attacks the body.</h2><h2 id=\"the-active-substance-hydrochlorothiazide-can-cause-an-unusual-reaction-resulting-in-a-decrease-in-vision-and-eye-pain-these-could-be-symptoms-of-fluid-accumulation-in-the-vascular-layer-of-the-eye-choroidal-effusion-or-an-increase-of-pressure-in-your-eye-and-can-happen-within-hours-to-weeks-of-taking-tolucombi-this-can-lead-to-permanent-vision-impairment-if-not-treated\">The active substance hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking Tolucombi. This can lead to permanent vision impairment, if not treated.</h2><h2 id=\"if-you-have-had-skin-cancer-or-if-you-develop-an-unexpected-skin-lesion-during-the-treatment-treatment-with-hydrochlorothiazide-particularly-long-term-use-with-high-doses-may-increase-the-risk-of-some-types-of-skin-and-lip-cancer-non-melanoma-skin-cancer-protect-your-skin-from-sun-exposure-and-uv-rays-while-taking-tolucombi\">If you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking Tolucombi.</h2><h2 id=\"if-you-experienced-breathing-or-lung-problems-including-inflammation-or-fluid-in-the-lungs-following-hydrochlorothiazide-intake-in-the-past-if-you-develop-any-severe-shortness-of-breath-or-difficulty-breathing-after-taking-tolucombi-seek-medical-attention-immediately-talk-to-your-doctor-before-taking-tolucombi-if-you-are-taking\">If you experienced breathing or lung problems (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past. If you develop any severe shortness of breath or difficulty breathing after taking Tolucombi, seek medical attention immediately. Talk to your doctor before taking Tolucombi, if you are taking:</h2><h2 id=\"digoxin\">digoxin.</h2><h2 id=\"any-of-the-following-medicines-used-to-treat-high-blood-pressure\">any of the following medicines used to treat high blood pressure:</h2><h2 id=\"an-ace-inhibitor-for-example-enalapril-lisinopril-ramipril-in-particular-if-you-have-diabetes-related-kidney-problems\">an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</h2><h2 id=\"aliskiren-you-must-tell-your-doctor-if-you-think-you-are-or-might-become-pregnant-tolucombi-is-not-recommended-in-early-pregnancy-and-must-not-be-taken-if-you-are-more-than-3-months-pregnant-as-it-may-cause-serious-harm-to-your-baby-if-used-at-that-stage-see-pregnancy-section-treatment-with-hydrochlorothiazide-may-cause-electrolyte-imbalance-in-your-body-typical-symptoms-of-fluid-or-electrolyte-imbalance-include-dry-mouth-weakness-lethargy-drowsiness-restlessness-muscle-pain-or-cramps-nausea-feeling-sick-vomiting-tired-muscles-and-an-abnormally-fast-heart-rate-faster-than-100-beats-per-minute-if-you-experience-any-of-these-you-should-tell-your-doctor-you-should-also-tell-your-doctor-if-you-experience-an-increased-sensitivity-of-the-skin-to-the-sun-with-symptoms-of-sunburn-such-as-redness-itching-swelling-blistering-occurring-more-quickly-than-normal-in-case-of-surgery-or-anaesthetics-you-should-tell-your-doctor-that-you-are-taking-tolucombi-tolucombi-may-be-less-effective-in-lowering-the-blood-pressure-in-black-patients-your-doctor-may-check-your-kidney-function-blood-pressure-and-the-amount-of-electrolytes-eg-potassium-in-your-blood-at-regular-intervals-see-also-information-under-the-heading-do-not-take-tolucombi--children-and-adolescents-the-use-of-tolucombi-in-children-and-adolescents-up-to-the-age-of-18-years-is-not-recommended-other-medicines-and-tolucombi-tell-your-doctor-or-pharmacist-if-you-are-taking-have-recently-taken-or-might-take-any-other-medicines-your-doctor-may-need-to-change-the-dose-of-these-other-medications-or-take-other-precautions-in-some-cases-you-may-have-to-stop-taking-one-of-the-medicines-this-applies-especially-to-the-medicines-listed-below-taken-at-the-same-time-with-tolucombi\">aliskiren. You must tell your doctor if you think you are (or might become) pregnant. Tolucombi is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). Treatment with hydrochlorothiazide may cause electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, nausea (feeling sick), vomiting, tired muscles, and an abnormally fast heart rate (faster than 100 beats per minute). If you experience any of these you should tell your doctor. You should also tell your doctor, if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal. In case of surgery or anaesthetics, you should tell your doctor that you are taking Tolucombi. Tolucombi may be less effective in lowering the blood pressure in black patients. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading Do not take Tolucombi . Children and adolescents The use of Tolucombi in children and adolescents up to the age of 18 years is not recommended. Other medicines and Tolucombi Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change the dose of these other medications or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same time with Tolucombi:</h2><h2 id=\"lithium-containing-medicines-to-treat-some-types-of-depression\">Lithium containing medicines to treat some types of depression.</h2><h2 id=\"medicines-associated-with-low-blood-potassium-hypokalaemia-such-as-other-diuretics-water-tablets-laxatives-eg-castor-oil-corticosteroids-eg-prednisone-acth-a-hormone-amphotericin-an-antifungal-medicine-carbenoxolone-used-to-treat-mouth-ulcers-penicillin-g-sodium-an-antibiotic-and-salicylic-acid-and-derivatives\">Medicines associated with low blood potassium (hypokalaemia) such as other diuretics, ('water tablets'), laxatives (e.g. castor oil), corticosteroids (e.g. prednisone), ACTH (a hormone), amphotericin (an antifungal medicine), carbenoxolone (used to treat mouth ulcers), penicillin G sodium (an antibiotic), and salicylic acid and derivatives.</h2><h2 id=\"medicines-that-may-increase-blood-potassium-levels-such-as-potassium-sparing-diuretics-potassium-supplements-salt-substitutes-containing-potassium-ace-inhibitors-cyclosporin-an-immunosuppressant-drug-and-other-medicinal-products-such-as-heparin-sodium-an-anticoagulant\">Medicines that may increase blood potassium levels such as potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, ACE inhibitors, cyclosporin (an immunosuppressant drug) and other medicinal products such as heparin sodium (an anticoagulant).</h2><h2 id=\"medicines-that-are-affected-by-changes-of-the-blood-potassium-level-such-as-heart-medicines-eg-digoxin-or-medicines-to-control-the-rhythm-of-your-heart-eg-quinidine-disopyramide-amiodarone-sotalol-medicines-used-for-mental-disorders-eg-thioridazine-chlorpromazine-levomepromazine-and-other-medicines-such-as-certain-antibiotics-eg-sparfloxacine-pentamidine-or-certain-medicines-to-treat-allergic-reactions-eg-terfenadine\">Medicines that are affected by changes of the blood potassium level such as heart medicines (e.g. digoxin) or medicines to control the rhythm of your heart (e.g. quinidine, disopyramide, amiodarone, sotalol), medicines used for mental disorders (e.g. thioridazine, chlorpromazine, levomepromazine) and other medicines such as certain antibiotics (e.g. sparfloxacine, pentamidine) or certain medicines to treat allergic reactions (e.g. terfenadine).</h2><h2 id=\"medicines-for-the-treatment-of-diabetes-insulins-or-oral-agents-such-as-metformin\">Medicines for the treatment of diabetes (insulins or oral agents such as metformin).</h2><h2 id=\"cholestyramine-and-colestipol-medicines-for-lowering-blood-fat-levels\">Cholestyramine and colestipol, medicines for lowering blood fat levels.</h2><h2 id=\"medicines-to-increase-blood-pressure-such-as-noradrenaline\">Medicines to increase blood pressure, such as noradrenaline.</h2><h2 id=\"muscle-relaxing-medicines-such-as-tubocurarine\">Muscle relaxing medicines, such as tubocurarine.</h2><h2 id=\"calcium-supplements-andor-vitamin-d-supplements\">Calcium supplements and/or vitamin D supplements.</h2><h2 id=\"anti-cholinergic-medicines-medicines-used-to-treat-a-variety-of-disorders-such-as-gastrointestinal-cramps-urinary-bladder-spasm-asthma-motion-sickness-muscular-spasms-parkinsons-disease-and-as-an-aid-to-anaesthesia-such-as-atropine-and-biperiden\">Anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson's disease and as an aid to anaesthesia) such as atropine and biperiden.</h2><h2 id=\"amantadine-medicine-used-to-treat-parkinson-s-disease-and-also-used-to-treat-or-prevent-certain-illnesses-caused-by-viruses\">Amantadine (medicine used to treat Parkinson s disease and also used to treat or prevent certain illnesses caused by viruses).</h2><h2 id=\"other-medicines-used-to-treat-high-blood-pressure-corticosteroids-painkillers-such-as-non--steroidal-anti-inflammatory-drugs-nsaids-medicines-to-treat-cancer-gout-or-arthritis\">Other medicines used to treat high blood pressure, corticosteroids, painkillers (such as non- steroidal anti-inflammatory drugs [NSAIDs]), medicines to treat cancer, gout, or arthritis.</h2><h2 id=\"if-you-are-taking-an-ace-inhibitor-or-aliskiren-see-also-information-under-the-headings-do-not-take-tolucombi-and-warnings-and-precautions-\">If you are taking an ACE-inhibitor or aliskiren (see also information under the headings Do not take Tolucombi and Warnings and precautions ).</h2><p>Digoxin. Tolucombi may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking Tolucombi. The effect of Tolucombi may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. acetylsalicyl acid or ibuprofen). Tolucombi with food and alcohol You can take Tolucombi with or without food. Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint. Pregnancy and breast-feeding Pregnancy You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Tolucombi before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Tolucombi. Tolucombi is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Tolucombi is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed. Driving and using machines Some people feel dizzy or tired when taking Tolucombi. If you feel dizzy or tired, do not drive or operate machinery. Tolucombi contains lactose, sorbitol and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Tolucombi 40 mg/12.5 mg contains 147.04 mg sorbitol in each tablet, which is equivalent to 5 mg/kg/day, if the body weight is 29.8 kg. Tolucombi 80 mg/12.5 mg and Tolucombi 80 mg/25 mg contain 294.08 mg sorbitol in each tablet, which is equivalent to 5 mg/kg/day, if the body weight is 58.8 kg. Patients weighing 58.8 kg or less must take into consideration that sorbitol is a source of fructose and if your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>"
}
},
{
"title" : "3. How to take tolucombi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take tolucombi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose of Tolucombi is one tablet a day. Try to take a tablet at the same time each day. You can take Tolucombi with or without food. The tablets should be swallowed with some water or other non-alcoholic drink. It is important that you take Tolucombi every day until your doctor tells you otherwise. If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once a day. If you take more Tolucombi than you should If you accidentally take too many tablets you may experience symptoms such as low blood pressure and rapid heartbeat. Slow heartbeat, dizziness, vomiting, reduced kidney function including kidney failure, have also been reported. Due to the hydrochlorothiazide component, markedly low blood pressure and low blood levels of potassium can also happen, which may result in nausea, sleepiness and muscle cramps and/or irregular heartbeat associated with the concomitant use of drugs such as digitalis or certain anti-arrhythmic treatments. Contact your doctor, pharmacist, or your nearest hospital emergency department immediately. If you forget to take Tolucombi If you forget to take a dose, do not worry. Take it as soon as you remember then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses. If you have further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some side effects can be serious and need immediate medical attention: You should see your doctor immediately if you experience any of the following symptoms: Sepsis* (often called \"blood poisoning\"), is a severe infection with whole-body inflammatory response, rapid swelling of the skin and mucosa (angioedema); blistering and peeling of the top layer of skin (toxic epidermal necrolysis); these side effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated they could be fatal. Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for Tolucombi. Possible side effects of Tolucombi: Common side effects (may affect up to 1 in 10 people): Dizziness. Uncommon side effects (may affect up to 1 in 100 people): Decreased blood potassium levels, anxiety, fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels. Rare side effects (may affect up to 1 in 1,000 people): Inflammation of the lung (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body s immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses; feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood. Adverse reactions reported with one of the individual components may be potential adverse reactions with Tolucombi, even if not observed in clinical trials with this product. Telmisartan In patients taking telmisartan alone the following additional side effects have been reported: Uncommon side effects (may affect up to 1 in 100 people): Upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), urinary tract infections, deficiency in red blood cells (anaemia), high potassium levels, slow heart rate (bradycardia), kidney impairment including acute kidney failure, weakness, cough. Rare side effects (may affect up to 1 in 1,000 people): Low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), serious allergic reaction (e.g. hypersensitivity, anaphylactic reaction, drug rash), low blood sugar levels (in diabetic patients), upset stomach, eczema (a skin disorder), arthrosis, inflammation of the tendons, decreased haemoglobin (a blood protein), somnolence. Very rare side effects (may affect up to 1 in 10,000 people): Progressive scarring of lung tissue (interstitial lung disease)** * The event may have happened by chance or could be related to a mechanism currently not known. ** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan. However, it is not known whether telmisartan was the cause. Hydrochlorothiazide In patients taking hydrochlorothiazide alone the following additional side effects have been reported: Common side effects (may affect up to 1 in 10 people): Feeling sick (nausea), low blood magnesium level. Rare side effects (may affect up to 1 in 1,000 people): Reduction in blood platelets, which increases risk of bleeding or bruising (small purple-red marks in skin or other tissue caused by bleeding), high blood calcium level, headache. Very rare side effects (may affect up to 1 in 10,000 people): Increased pH (disturbed acid-base balance) due to low blood chloride level, acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion). Side effects of unknown frequency (frequency cannot be estimated from the available data): Inflammation of the salivary gland, skin and lip cancer (Non-melanoma skin cancer), decreases in the number (or even lack) of cells in the blood, including low red and white blood cell count, serious allergic reactions (e.g. hypersensitivity, anaphylactic reaction), decreased or loss of appetite, restlessness, light-headedness, blurred or yellowing of vision, decrease in vision and eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute myopia or acute-angle closure glaucoma), inflammation of blood vessels (vasculitis necrotising), inflamed pancreas, upset stomach, yellowing of the skin or eyes (jaundice), lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body s immune system attacks the body); skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, rash, redness of the skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or impaired kidney function, glucose in the urine (glycosuria), fever, impaired electrolyte balance, high blood cholesterol levels, decreased blood volume, increased levels of glucose, difficulties in controlling blood/ urine levels of glucose in patients with a diagnosis of diabetes mellitus, or fat in the blood. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store tolucombi",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store tolucombi"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and blister after EXP . The expiry date refers to the last day of that month. This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"what-tolucombi-contains\">What Tolucombi contains</h2><h2 id=\"the-active-substances-are-telmisartan-and-hydrochlorothiazide-each-tablet-contains-40-mg-telmisartan-and-125-mg-hydrochlorothiazide-each-tablet-contains-80-mg-telmisartan-and-125-mg-hydrochlorothiazide-each-tablet-contains-80-mg-telmisartan-and-25-mg-hydrochlorothiazide\">The active substances are telmisartan and hydrochlorothiazide. Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide. Each tablet contains 80 mg telmisartan and 12.5 mg hydrochlorothiazide. Each tablet contains 80 mg telmisartan and 25 mg hydrochlorothiazide.</h2><p>The other ingredients are: hydroxypropylcellulose, lactose monohydrate, magnesium stearate, mannitol, meglumine, povidone (K30), red ferric oxide (E172) only in 40 mg/12.5 mg and 80 mg/12.5 mg tablets, silica colloidal anhydrous, sodium hydroxide (E524), sodium stearyl fumarate, sorbitol (E420) and yellow ferric oxide (E172) only in 80 mg/25 mg tablets. See section 2 \"Tolucombi contains lactose, sorbitol and sodium\". What Tolucombi looks like and contents of the pack 40 mg/12.5 mg tablets: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 15 mm x 7 mm. 80 mg/12.5 mg tablets: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm. 80 mg/25 mg tablets: White to yellowish white on one side and yellow marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm. Blisters (OPA/Al/PVC foil//Al foil): 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1 and 100 x 1 tablet in a box. Blisters (OPA/Al/PE foil with desiccant//Al foil): 14 x 1 and 98 x 1 tablet in a box. Not all pack sizes may be marketed. Marketing Authorisation Holder KRKA, d.d., Novo mesto, marje ka cesta 6, 8501 Novo mesto, Slovenia Manufacturers KRKA, d.d., Novo mesto, marje ka cesta 6, 8501 Novo mesto, Slovenia KRKA-POLSKA Sp. z o.o., ul. R wnoleg a 5, 02-235 Warszawa, Poland TAD Pharma GmbH, Heinz-Lohmann-Stra e 5, 27472 Cuxhaven, Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien KRKA Belgium, SA. T l/Tel: +32 (0) 487 50 73 Lietuva UAB KRKA Lietuva Tel: + 370 5 236 27</p><p>Te .: + 359 (02) 962 34 Luxembourg/Luxemburg KRKA Belgium, SA. T l/Tel: +32 (0) 487 50 73 62 (BE) esk republika KRKA R, s.r.o. Tel: + 420 (0) 221 115 Magyarorsz g KRKA Magyarorsz g Kereskedelmi Kft. Tel.: + 36 (1) 355 8Danmark KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) Malta E. J. Busuttil Ltd. Tel: + 356 21 445 Deutschland TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 Nederland KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) Eesti KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 Norge KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE)</p><p>KRKA<br/>: + 30 2100101 sterreich KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 Espa a KRKA Farmac utica, S.L. Tel: + 34 911 61 03 Polska KRKA-POLSKA Sp. z o.o. Tel.: + 48 (0)22 573 7France KRKA France Eurl T l: + 33 (0)1 57 40 82 Portugal KRKA Farmac utica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 Hrvatska KRKA - FARMA d.o.o. Tel: + 385 1 6312 Rom nia KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3Slovenija KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 sland LYFIS ehf. S mi: + 354 534 3Slovensk republika KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 Italia KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8Suomi/Finland KRKA Finland Oy Puh/Tel: +358 20 754 5 KI.PA. (PHARMACAL) LIMITED : + 357 24 651 Sverige KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) Latvija KRKA Latvija SIA Tel: + 371 6 733 86 United Kingdom (Northern Ireland) KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp524ff85a84e081511904d5b0500b5714",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp524ff85a84e081511904d5b0500b5714",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp524ff85a84e081511904d5b0500b5714\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp524ff85a84e081511904d5b0500b5714</b></p><a name=\"mp524ff85a84e081511904d5b0500b5714\"> </a><a name=\"hcmp524ff85a84e081511904d5b0500b5714\"> </a><a name=\"mp524ff85a84e081511904d5b0500b5714-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/821/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Tolucombi 40 mg/12.5 mg tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/13/821/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Tolucombi 40 mg/12.5 mg tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
